Key result
PCSK9 regulates hepatic triglyceride metabolism, emerging as a potential target in steatotic liver diseases.
Why the study?
Emerging clinical and preclinical evidence suggests PCSK9 influences hepatic triglyceride metabolism beyond cholesterol clearance, but its mechanisms and therapeutic implications remain to be clarified.
Summarizes emerging evidence that PCSK9 regulates hepatic triglyceride metabolism in addition to cholesterol clearance, suggesting new therapeutic avenues for dyslipidemias and steatotic liver diseases.
Answers are grounded in this paper and cite their sources.
PCSK9 may modulate hepatic triglycerides beyond LDL clearance; leaves open whether this affects steatosis or requires targeted trials.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a central regulator of cholesterol homeostasis, primarily by promoting the lysosomal degradation of the hepatic low-density lipoprotein receptor (LDLR). However, emerging clinical and preclinical evidence suggests that PCSK9's influence extends beyond cholesterol clearance to the modulation of hepatic triglyceride metabolism. This review examines the biochemical mechanisms by which PCSK9 regulates intrahepatic triglyceride steady-state concentrations, highlighting its role in the assembly and lipidation of very low-density lipoproteins (VLDL) through both LDLR-dependent and independent mechanisms. We further discuss the integration of PCSK9 activity with hepatic lipid-sensing mechanisms and de novo lipogenesis. Finally, we evaluate the impact of current PCSK9-targeted therapies on the hepatic lipidome and contextualize these findings within the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). By highlighting the non-canonical roles of PCSK9, we aim to critically assess its potential as a multifaceted therapeutic target for dyslipidemias and steatotic liver diseases.
No takes yet. Share an insight, caveat, or question.
Palenque-Blanco et al. (2026) conducted a review in Dyslipidemias and metabolic dysfunction-associated steatotic liver disease (MASLD). PCSK9 was evaluated. PCSK9 regulates hepatic triglyceride metabolism and VLDL assembly through LDLR-dependent and independent mechanisms, emerging as a potential therapeutic target for steatotic liver diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: